PRO-DEX, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PRO-DEX, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $600.00K.
- PRO-DEX, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $601.00K.
- PRO-DEX, INC. payments for repurchase of common stock for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- PRO-DEX, INC. payments for repurchase of common stock for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- PRO-DEX, INC. payments for repurchase of common stock for fiscal 2026 was $3.41M, a 2.74% decline from fiscal 2025.
- PRO-DEX, INC. payments for repurchase of common stock for fiscal 2025 was $3.50M, a 0.03% decline from fiscal 2024.
- PRO-DEX, INC. payments for repurchase of common stock for fiscal 2024 was $3.50M, a 126.57% increase from fiscal 2023.
- PRO-DEX, INC. payments for repurchase of common stock for fiscal 2023 was $1.55M, a 3.67% decline from fiscal 2022.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-03 | $3.41M 10-K · filed 2026-09-03 |
| 2026-03-31 | $601.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-30 | |
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-03 | $3.50M 10-K · filed 2026-09-03 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-30 | $5.18M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-01-29 | $6.90M derived: sum of 4 quarters · filed 2026-01-29 |
| 2024-09-30 | $2.31M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | $3.50M 10-K · filed 2025-09-04 |
| 2024-03-31 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-01 | |
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-05 | $1.55M 10-K · filed 2024-09-05 |
| 2023-03-31 | $198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-02 | $1.90M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $995.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-08 | $2.28M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | $354.00K 10-Q · filed 2023-11-02 | $1.86M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-13 | $1.61M 10-K · filed 2023-10-13 |
| 2022-03-31 | $583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-04 | $2.75M derived: sum of 4 quarters · filed 2023-10-13 |
| 2021-12-31 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-02 | |
| 2021-09-30 | $95.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-13 | $5.54M 10-K · filed 2023-10-13 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $2.71M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-09 | $3.39M 10-K · filed 2021-09-09 |
| 2020-03-31 | $762.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-06 | $4.29M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-04 | $3.64M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | $681.00K 10-Q · filed 2020-11-05 | $3.55M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-10 | $3.98M 10-K · filed 2020-09-10 |
| 2019-03-31 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-07 | $2.88M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06 | |
| 2018-09-30 | $1.11M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-12 | $220.00K 10-K · filed 2019-09-12 |
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-13 | $312.00K 10-K · filed 2018-09-13 |
| 2017-03-31 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-10 | $764.00K derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | |
| 2016-09-30 | $49.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-14 | $454.00K 10-K · filed 2017-09-14 |
| 2015-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-15 | $154.00K 10-K · filed 2016-09-15 |
| 2015-03-31 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-12 | |
| 2012-06-30 | $6.00K 10-K · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |